The Global PD-1 and PD-L1 Inhibitors Market was valued at USD 33.1 billion in 2020 and it is expected to reach USD 117.2 billion by 2027, with a CAGR of 19.8%, during the forecast period.
PD1 (Programmed Cell Death) inhibitor and PD (Programmed Cell Death) L1 inhibitor is the prominent immune checkpoint inhibitors found in some anticancer drugs. PD-1 and PD-L1 inhibitors is the capability of T-cells to destroy the cancer cells. As per the NCI (National Cancer Institute), PD-1 and PD-L1 inhibitors supports to have body responses in check. The antibodies that support the PD-1 and PD-L1 inhibitors market are pembrolizumab, nivolumab, durvalumab, atezolizumab, and avelumab.
The driving factors influencing the global PD-1 and PD-L1 inhibitors market includes emergence of monoclonal antibody which target immune check points and results to give an enormous development in the cancer therapeutics. According to JTO clinical and research report with the chemotherapy the PD-1 and PD-L1 inhibitors also use as first line treatment for (non- small cell lung cancer) NSCLC. Additionally, the PD-1 and PD-L1 inhibitors has ability to improve antitumor immunity.
Thus, it gives rise to improve immune- oncology therapy which is considerably the propelling factor for the growth of the global PD-1 and PD-L1 inhibitors market. Moreover, the requirement to reduce mortality rate due to metastatic cancer is another fuelling factor for the growth of the global PD-1 and PD-L1 inhibitors market.
The Global PD-1 and PD-L1 Inhibitors Market Segmentation:
By Type
By Application
By Region
Based on type, PD-1 inhibitor segment is dominating segment and expected to show significant growth over the forecast period due to increasing demand among the cancer patients
Based on type, the global PD-1 and PD-L1 inhibitors market can be segmented as PD-1 inhibitor and PD-L1 inhibitor. Among these, PD-1 inhibitor sub- segment holds the largest share in the PD-1 and PD-L1 inhibitors market and is expected to show a significant growth during the forecast period. Rise in the approval and prescription of the drug nivolumab and pembrolizumab drives the growth of the PD-1 and PD-L1 inhibitors market.
Further, since from the endorsement of first PD-1 inhibitor (KEYTRUDA) by the FDA in 2014, the adoption of KEYTRUDA rises for the (non–small cell lung cancer) NSCLC, melanoma, (head and neck squamous cell cancer) HNSCC drives the growth of PD-1 and PD-L1 inhibitor segment market.
Based on applications, the solid tumours segment is expected to show a high growth during the forecast period due to rise in number of cancer patients
Based on applications, the global PD-1 and PD-L1 inhibitors market can be segmented as solid tumours, tumours related to blood. The solid tumours segment has accounted for the largest share in the PD-1 and PD-L1 inhibitors market in 2020 and expected to remain constant to hold its market position throughout the forecast period. Solid tumours include muscles, bones, and organs. According to WHO (World Health Organization) across the globe, the cancer is a second leading factor causing death, in 2018, it has accounted over 9.6 Mn death due to solid tumour. Therefore, the solid tumours segment drives the growth of global market.
Based on region, North America region is the dominating market and shows significant growth for the PD-1 and PD-L1 inhibitors market throughout the forecast period
Based on region, the global PD-1 and PD-L1 inhibitors market can be segmented as North America, Europe, Asia Pacific, Latin America, and Middle East & Africa. The North America region is dominating region for the global market due to the high investment in the R&D, awareness among the population, and large volume of patient population.
However, Europe region is second dominating region in the PD-1 and PD-L1 inhibitors market on account of the high prevalence of lung cancer due to lifestyle habits such as smoking, alcohol consumption and unhealthy diet. Furthermore, the provoking massive research for PD-1 and PD-L1 inhibitors is minimizing the death rate related to cancer.
Company Profiles and Competitive Intelligence
The key players operating in the global PD-1 and PD-L1 inhibitors market are:
The report also provides an in-depth analysis of market dynamics such as drivers, restraints, opportunities, and challenges
Drivers
Restraints
Opportunity
Challenges
COVID-19 Impact on the Global PD-1 and PD-L1 Inhibitors Market
Covid-19 has highly affected the industries in terms of growth, economy, health, and mental wellbeing of every individual. In this challenging situation, every industry is trying to give best services in terms of quality and safety. The outbreak of COVID-19 has not much affected the PD-1 and PD-L1 inhibitors market due to coronavirus.
The report also provides in-depth analysis of key global PD-1 and PD-L1 inhibitors market trends
The report also provides an in-depth analysis of recent news developments and investments
The unique insights provided by this report also includes the following:
Ask for free product review call with the author
Share your specific research requirements for a customized report
Request for due diligence and consumer centric studies
Request for study updates, segment specific and country level reports
Log in / Register
